Compositions, methods of administration and uses for trivalent dengue virus formulations

Inventors: Dan T. Stinchcomb (Fort Collins, CO); Joseph N. Brewoo (Madison, WI); Jorge E. Osorio (Mount Horeb, WI); Charalambos D. Partidos (Chicago, IL)

Assignee: Takeda Vaccines, Inc.

A61K39/12 A61K45/06 A61K2039/5254 A61K2039/5256 A61K2039/70 C12N2770/24134

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,878,031
App. No.: 14/652,066
Granted: Jan 30, 2018
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Embodiments of the present invention report compositions and methods for vaccinating a subject using trivalent dengue virus vaccine compositions. In some embodiments, more than one vaccine composition may be administered to a subject in different anatomical locations in order to induce a rapid response to at least three of four dengue virus serotypes. In certain embodiments, administration of a trivalent dengue virus vaccine composition can be combined with administration of a monovalent dengue virus vaccine composition.

Claims (26)

1. A method for inducing neutralizing antibodies in a subject against three or more dengue virus serotypes, the method comprising;

administering at least a second dose of a live, attenuated dengue virus immunogenic composition comprising a single live, attenuated dengue virus chimera or a monovalent live, attenuated dengue virus on the same day or up to 180 days after administration of the first dose of the single trivalent dengue virus immunogenic composition.

2. A method for inducing neutralizing antibodies in a subject against three or more dengue virus serotypes, the method comprising;

administering a first dose of a single trivalent dengue virus immunogenic composition comprising a mixture of three or more different live, attenuated dengue viruses, wherein the mixture comprises at least three dengue virus serotypes comprising dengue-dengue chimeras, wherein the dengue-dengue chimeras comprise one or more structural elements of dengue-1, dengue-2, dengue-3 or dengue-4, and one or more structural or non-structural elements of a live, attenuated dengue virus, and wherein three of four dengue virus serotype structural elements are present in the single trivalent dengue virus immunogenic composition, wherein the single trivalent dengue virus immunogenic composition comprises constructs comprising a predetermined ratio of dengue virus serotype constructs comprising dengue-1, dengue-2, and dengue-3; dengue-1, dengue-3, and dengue-4; dengue-1, dengue-2, and dengue-4; or dengue-2, dengue-3 and dengue-4, wherein concentration measured by plaque forming units (pfus) of at least one dengue virus serotype is higher in concentration than at least one other dengue virus serotype in the single trivalent dengue virus immunogenic composition; and

3. The method of claim 2 , wherein the higher concentration is 2 to 100,000 fold higher concentration.

4. A method for inducing neutralizing antibodies in a subject against three or more dengue virus serotypes, the method comprising;

administering at least a second dose of a live, attenuated dengue virus immunogenic composition comprising a single live, attenuated dengue virus chimera or a monovalent live, attenuated dengue virus on the same day, wherein administration of the at least second immunogenic composition on the same day comprises administering at a second anatomical site using different modes of administration.

5. The method of claim 1 , wherein at least one additional booster is administered to the subject less than 180 days after the same day immunogenic compositions.

6. The method of claim 1 , wherein at least one additional booster is administered to the subject 90 days or less after the same day administrations.

7. The method of claim 1 , further comprising administering at least one additional immunogenic agent to the subject.

8. A method for inhibiting dengue virus infection in a subject, the method comprising:

administering to the subject a first immunogenic composition of a trivalent composition of live, attenuated dengue virus comprising three dengue virus serotypes dengue-1, dengue-2, and dengue-3; dengue-1, dengue-3, and dengue-4; dengue-1, dengue-2, and dengue-4; or dengue-2, dengue-3 and dengue-4; and

administering consecutively to the subject at least a second administration of an immunogenic composition of live, attenuated dengue virus comprising a single dengue virus serotype (monovalent), the first and second immunogenic compositions are administered to the subject in different anatomical sites on the subject, wherein the single dengue virus serotype comprises a dengue virus serotype not having a structural protein in the trivalent dengue virus immunogenic composition.

9. The method of claim 8 , wherein the trivalent dengue virus immunogenic compositions comprise unequivalent distribution of the three dengue virus serotypes in the immunogenic composition where concentration of one serotype can vary from 2 to 100,000 fold compared to another.

10. The method according to claim 3 , wherein the three dengue virus serotypes are each in a predetermined ratio, and wherein the trivalent immunogenic composition comprises dengue-4 (DEN-4) at 2 to 100,000 times higher concentration than the other two dengue virus serotypes.

11. The method of claim 4 , wherein the trivalent immunogenic composition comprises dengue-dengue chimeras having attenuated dengue-2 virus backbones.

12. The method of claim 11 , wherein the attenuated dengue-2 virus is strain PDK-53.

13. A method for inducing neutralizing antibodies in a subject against three or more dengue virus serotypes, the method comprising;

14. A method for inducing neutralizing antibodies in a subject against three or more dengue virus serotypes, the method comprising;

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2017

From: STINCHCOMB, DAN T.; BREWOO, JOSEPH N.; OSORIO, JORGE E.; PARTIDOS, CHARALAMBOS D.

To: INVIRAGEN, INC.

Reel/Frame 044201/0180 →

Continuity (2)

Provisional Application 61737679 · Dec 14, 2012

Related Publication 20150335727A1 · Nov 26, 2015